Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database.
Iris G M SchoutenMarise J KasteleynRoula TsonakaRobert BalsAlice Margaret TurnerIlaria FerrarottiAngelo G CorsicoBeatriz Lara GallegoMarc MiravitllesRobert A StockleyJan StolkPublished in: ERJ open research (2021)
In our study population, we could not detect a significant difference in the annual decline of FEV1 by AAT augmentation treatment over a mean period of 8.6 years. Other approaches are needed to validate any benefit of augmentation therapy.